UPDATED: Siedle, Raimondo Critic, to be Awarded $48M in SEC

New Post Public Reply Private Reply Replies (1) Message Board
AlanC 4kids #3596
394
UPDATED: Siedle, Raimondo Critic, to be Awarded $48M in SEC Record Whistleblower Case
Twitter Favicon Facebook Favicon Digg Favicon Reddit Favicon StumbleUpon Favicon del.icio.us Favicon Email to a friend Permalink
Saturday, July 22, 2017
GoLocalProv News Team



Ted Siedle, slated to receive the biggest whistleblower award in U.S. history

GoLocal has learned that Ted Siedle, the Forbes columnist, critic of Gina Raimondo’s investment strategy in hedge funds, and sometimes GoLocal contributor, is in line to be awarded $48 million of more than $70 million in a record award by the U.S. Securities and Exchange Commission case.
The final numbers will not be finalized for approximately 60 days.

Siedle, reached by phone in Florida, refused to comment on the potential award and has not made any public comment on the record award.

The Case

The case involves a total of six JP Morgan whistleblowers — one identified as former JP Morgan rep Johnny Burris and the other GoLocal has learned is Siedle. There are four other identified whistleblowers, but none of them are to receive awards as presently structured.

According to documents leaked on Thursday to the national financial press, “The Claims Review Staff preliminarily determined to recommend to the Commission that Claimant #1 and Claimant #2 voluntarily provided original information to the Commission that led to the successful enforcement…”

"Many times the government gets a bad rap," said Burris, one of the six whistleblowers, who provided a redacted copy of the SEC letter. "With this award, the SEC and the [Commodity Futures Trading Commission] have done the peoples' work and they should be commended for that,“ Burris told On Wall Street.

As a part of the government action, JPMorgan agreed to pay over $300 million in regulatory fines in 2016.

CFTC is expected to make an additional monetary whistleblower awards in this case within the next month after the agency’s new regulations go into effect. That may increase the amount to the two award recipients.

Ryan White spokesperson of the SEC refused to confirm Burris and Siedle, "The agency has no comment."




Governor Gina Raimondo

Raimondo Criticizes Siedle
Over the past three plus years, Siedle has repeatedly raised concerns about Raimondo’s management of the RI employees pension fund and has repeatedly said that any money saved by pension reform has been squandered in fees to hedge funds.

Raimondo dismissed Siedle's criticism from the onset - he is a columnist for Forbes and a former SEC investigator - she said he is an agenda driven “blogger.”

The rivalry by Siedle and Raimondo goes back to when Raimondo was Treasurer and Siedle criticized her investment strategy which focused a higher proportion than most states in investment in alternative investment aka, hedge funds.

After GoLocal unveiled the issues raised by Siedle, the Providence Journal reported a few month later -- in October of 2013 that Raimondo said, “There is nothing new here (of a Siedle report). This is just a rehash of criticism we have seen from this person in the past ... He is making tens of thousands of dollars, paid by opponents of pension reform, to poke holes in me...and our pension reform efforts.″

On Thursday on GoLocal LIVE, then Governor Chafee criticized Raimondo for not only her investment strategies as Treasurer, but also her claims about her role in pension reform. "And my final issue [on pension reform] is performance," said Chafee. "Retirees were promised their COLA would come back when the fund reached a certain solvency -- and now the hedge funds [investments] pushed that out further. The investments were terrible with the rapaciously high fees. The retirees have to be livid,” Chafee said.

Earlier this year, now-Treasurer Seth Magaziner rejected Raimondo’s investment strategy and dramatically lowered the RI retirement’s system investment in hedge funds.

"We are moving away from the high-cost hedge funds that have failed to meet expectations while charging unacceptably high fees. Our new Back to Basics strategy will improve performance and reduce risk, providing a more secure future for Rhode Island public employees and all taxpayers,” said Magaziner.

In one Forbes column, Siedle wrote about Raimondo, "The wreckage related to Raimondo’s failed stint as a small-time venture capitalist is finally out in the open for all Rhode Islanders to see. The Point Judith II fund she pitched to the Employees Retirement System of Rhode Island (in which the pension risked $5 million) has returned a pathetic -1.1 percent over the past almost ten years—after paying her rich fees of 2.5 percent. If making money off your investors defines success, then Raimondo’s a superstar."




SEC - record award

Largest Award Ever When Finalized
In 2014, the SEC announced the then-largest whistleblower award, when it announced an expected award of more than $30 million to a whistleblower who provided key original information that led to a successful SEC enforcement action.

That award was then the largest made by the SEC’s whistleblower program to date and the fourth award to a whistleblower living in a foreign country, demonstrating the program’s international reach.

“This whistleblower came to us with information about an ongoing fraud that would have been very difficult to detect,” said Andrew Ceresney, Director of the SEC’s Division of Enforcement in 2014. “This record-breaking award sends a strong message about our commitment to whistleblowers and the value they bring to law enforcement.”

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ImmVira's Bladder Cancer Trials: Promising Data Revealed

Updated Category News Views 3

Tackling Bladder Cancer with Innovation In a world where every budding biotech claims they're on the cusp of revolutionizing cancer treatment, ImmVira's recent data on their oncolytic immunotherapy, MVR-T3011, stands out like a bright flash in a murky market. Presented at the prestigious European Society for Medical Oncology (ESMO) Congress 2026 in Suzhou, these updates...

Continue Reading
Resilience: From Trauma to Shielding Powerhouses

Updated Category News Views 6

A Childhood Steeped in Shadows If you think it's all Wall Street pulse for me, think again. Sometimes you stumble upon stories that hit the gut with more force than any market crash. Enter David Seymour's tale, wrapped up in his newly released autobiography from Palmetto Publishing, bearing the intriguingly gritty title: From paperboy to Secret Service Special Agent. This...

Continue Reading
ThreatLocker Launches Global AI Awareness Campaign

Updated Category News Views 4

Kicking Off with Pop Culture Pizzazz Ah, the sweet sound of a campaign that knows how to tug at the heartstrings of nostalgia. ThreatLocker has gotten creative with its latest strategy to get people buzzing about AI safety. They're unleashing a worldwide campaign themed around 'Terminator 2.' Now that's a throwback! If you've ever caught yourself wide-eyed at the edge of...

Continue Reading
Camel Group Expands Battery Portfolio at Canton Fair

Updated Category News Views 3

A Grand Display at the Canton Fair Well, here's one you don't see every day: Camel Group putting on quite the show at the 140th China Import and Export Fair, better known to us as the Canton Fair. Kicked off on October 15, 2026, in Guangzhou, this grand event paraded 'Advanced Manufacturing' as its theme, and Camel's booth was packed to the brim with what might just be...

Continue Reading
ZPMC's Wind Power and Port Projects Earn Top Honors

Updated Category News Views 1

Wind Farms and Ports: A Winning Formula National applause rings out for Shanghai Zhenhua Heavy Industries Co., Ltd. (ZPMC) as they snagged top honors in the recent National Quality Engineering Awards. It's about time folks recognized the heavy lifting these projects do in reshaping our energy and port infrastructure. Two of their standout projects walked away with...

Continue Reading
Encompass Health Expands With Texas Rehab Hospital

Updated Category News Views 6

A New Chapter in San Antonio's Healthcare Landscape Breaking ground in Texas, Encompass Health has unveiled its latest addition: a 50-bed hospital in San Antonio's Westover Hills. With sheer determination, the largest owner of inpatient rehabilitation hospitals in the U.S. has made its mark, and this isn't just any facility—at over 54,000 square feet, it's a hub for...

Continue Reading
Union Alarmtronic Joins Forces with Pye-Barker in Key Sale

Updated Category News Views 3

A Key Merger in Security Sector Here's a deal that's got the market talking: Union Alarmtronic, a stalwart in the security systems arena, has tied the knot with Pye-Barker Fire & Safety, one of the biggest names in fire protection and life safety. This move isn't just another line in the 'mergers & acquisitions' logbook; it's a strategic shift that underscores the growing...

Continue Reading
Duni Group Faces Ups and Downs in Q3 2026

Updated Category News Views 1

Navigating Choppy Waters: Duni's Third Quarter 2026 Alright, folks, let's dive into the latest from Duni Group—a company feeling the pinch but pushing through with some resilience. The third quarter 2026 report has just landed, and while some numbers are headed up, plenty are a bit of a gut punch. This isn't a crisis, but it's no smooth sailing either. Let's cut through...

Continue Reading
Groundbreaking Sale: Lani Automotive Acquires Iowa Dealership

Updated Category News Views 6

A shift in the automotive retail world takes place with Lani Automotive Group's latest move. They've just picked up their first franchised dealership, Mount Pleasant Chevrolet GMC Chrysler Dodge Jeep Ram in Iowa. It's a mouthful, sure, but it packs a punch in terms of potential growth. Why This Sale Stands Out The deal was brokered by Performance Brokerage Services, which...

Continue Reading
Marengo: Bold Moves in TMB-H Tumor Treatment

Updated Category News Views 0

A New Hope for Tough Tumors? Marengo Therapeutics is stirring up the oncology world with some intriguing Phase 2 results from their STARt-001 clinical trial, revealing invikafusp alfa's potential as a single-agent therapy. This hasn’t been a walk in the park, mind you; we're talking about dealing with TMB-H solid tumors that typically thumb their noses at immune...

Continue Reading
iv>